Numerous studies have shown that homologous recombination deficiency (HRD) is a genome-wide biomarker present in high grade ovarian and breast cancers. A cancer therapeutic class, PARP inhibitors, induce synthetic lethality in tumors with high levels of HRD. When Genome-wide HRD severity is scored, studies show these scores correlate to PARP inhibitor response. In this webinar the speakers will review their experiences using OncoScan, a whole-genome research microarray, as an alternative to NGS to detect Long Scale State transitions (LST), Loss of Heterozygosity (LOH), Telomeric Allelic Imbalance (TAI) and Whole Genome Doubling (WGD) events, to create HRD Scores.

Learning Objectives:

1. Review linking HRD scaring biology to PARP inhibitor response.

2. Explain the methods for detecting HRD – the benefits and challenges.

3. Discuss OncoScan successfully in a clinical research lab to understand HRD in samples.

4. Summarize future directions for HRD into new tumor entities and technology development.